6541.TW Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 08:30):

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States...

Stats
Dzisiejszy wolumen	419 107
Średni wolumen	345 448
Kapitalizacja rynkowa	7.20B
EPS	TWD0 ( 2024-03-14 )
Następna data zysków	( TWD0 ) 2024-05-07
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-2.78
ATR14	TWD0.0870 (0.19%)

Wolumen Korelacja

Długi: 0.17 (neutral)

Krótki: 0.99 (very strong)

Signal:(45.463) Expect same movement, but be aware

Tanvex BioPharma, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tanvex BioPharma, Inc. Korelacja - Waluta/Towar

0.01
( neutral )

-0.04
( neutral )

0.00
( neutral )

0.02
( neutral )

-0.50
( neutral )

0.00
( neutral )

Tanvex BioPharma, Inc. Finanse

Annual	2023
Przychody:	TWD61.41M
Zysk brutto:	TWD-265.13M (-431.73 %)
EPS:	TWD-16.42

FY	2023
Przychody:	TWD61.41M
Zysk brutto:	TWD-265.13M (-431.73 %)
EPS:	TWD-16.42

FY	2022
Przychody:	TWD22.40M
Zysk brutto:	TWD-19.35M (-86.36 %)
EPS:	TWD-13.55

FY	2021
Przychody:	TWD5.41M
Zysk brutto:	TWD3.55M (65.67 %)
EPS:	TWD-5.70

Financial Reports:

No articles found.

Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Aktualne aktualizacje dla Tanvex BioPharma, Inc. [6541.TW]

Upcoming Earnings Alert